BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Artificial Intelligence

Applying Artificial Intelligence And Bioinformatics To Create Complete Picture Of Immune System

by Andrii Buvailo, PhD  (contributor )   •   April 4, 2018  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# AI & Digital   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Nowadays, the brightest innovations usually happen at the intersection of different disciplines and technologies. A recent scientific achievement by Dr. Carsten Krieg, a researcher at Hollings Cancer Center (HCC), Medical University of South Carolina, is not an exception to this observation.
With an ambitious goal in mind to advance the field of cancer immunotherapy, Dr. Krieg combines a very powerful analytical technique -- mass cytometry, with artificial intelligence (AI), machine learning and bioinformatics tools to visualize the obtained experimental data and have a bird’s-eye view of the immune system.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

Mass cytometry, or CyTOF (cytometry by time-of-flight), is a variation of flow cytometry in which antibodies are labeled with heavy metal ions (in the case of Dr. Krieg’s experiments -- with rare metals), rather than fluorochromes, and then time-of-flight mass spectrometry is used for readout.

Basically, Dr. Krieg used this approach to stain cells using rare metal-conjugated antibodies that target surface and intracellular proteins to visualize what was happening on a cellular level. After staining, the cells are ionized using an inductively-coupled plasma. The ions derived from each stained cell are then detected in a mass spectrometer.

According to Dr. Krieg, this technique can potentially identify up to 100 markers per cell, but practically speaking, results on around 40 markers are more realistic to achieve. 

Continue reading

This content available exclusively for BPT Mebmers

 BPT Membership 

Topics: AI & Digital   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

You may also be interested to read:

2018 Brings A Surge Of Activity In The “AI For Drug Discovery” Space
by Andrii Buvailo
Network Driven Drug Discovery Using AI
by Andrii Buvailo
Genenerative AI Models In Small Molecule Drug Discovery: The Open Challenge To Create A Unified Benchmark
by Mostapha Benhenda

 

#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.